Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.

Nicola C VennLibby HuangLenka HovorkováWalter MuskovicMarie WongTamara LawSusan L HeatleySeong Lin KhawTom ReveszLuciano Dalla PozzaPeter J ShawChris FraserAndrew S Moore Siobhan CrossKaterina BendakMurray D Norris Michelle J Henderson Deborah L White Mark J Cowley Toby N TrahairJan ZunaRosemary Sutton

Published in: British journal of cancer (2022)

MRD monitoring based on patient-specific assays detecting gene fusions or recurrent assays for IKZF1-deletions is feasible and provides good alternatives to Ig/TCR tests to monitor MRD in ABL-class ALL.

Keyphrases

tyrosine kinase
high throughput
chronic myeloid leukemia
liver failure
acute lymphoblastic leukemia
intensive care unit
emergency department
respiratory failure
genome wide
copy number
gene expression
dna methylation
immune response
genome wide identification
dendritic cells